Biological/Research Material for HIV Vaccine Research
Posted Oct 11 2009 5:00pm
Description of Invention: Offered for licensing is a recombinant attenuated vaccinia virus, MVA, that expresses SIV 239gagpol. The materials can be used for research purposes and in particular in the area of HIV/AIDS vaccines.
Plasmid insertion vector pJH-4, containing the foreign gene SIV 239 GagPol controlled by vaccinia early/late promoter, inserts into del III of attenuated vaccinia MVA virus to make recombinant MVA virus. The resulting recombinant virus made from pJH4, MVA/SIV239gagpol, expresses the SIV 239gagpol gene and thus can be used to conduct vaccine studies in animal models such as Rhesus macaques.
The list of publications shown below demonstrates the usefulness of this biological material in HIV vaccine research.
Applications: Research reagents useful in research and development in the area of HIV/AIDS vaccines.
Development Status: Fully developed. Material has been used extensively in research.
Research Material -- patent protection is not being pursued for this technology
Related Technologies: US, Patent No. 7,045,313, Issued 16 May 2006, Reference No. E-552-1982/2 US, Patent No. 7,015,024, Issued 21 Mar 2006, Reference No. E-552-1982/2 US, Patent No. 6,998,252, Issued 14 Feb 2006, Reference No. E-552-1982/2 US, Patent No. 7,045,136, Issued 16 May 2006, Reference No. E-552-1982/2 PCT, Application No. PCT/US83/01863 filed 28 Nov 1983, Reference No. E-552-1982/2
An abstract describing these technologies may be viewed at http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2000.
RR Amara, F Villinger, JD Altman, SL Lydy, SP O'Neil, SI Staprans, DC Montefiori, Y Xu, JG Herndon, LS Wyatt, MA Candido, NL Kozyr, PL Earl, JM Smith, HL Ma, BD Grimm, ML Hulsey, J Miller, HM McClure, JM McNicholl, B Moss, HL Robinson. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001 Apr 6;292(5514):69-74. [ PubMed abs ]
PL Earl, LS Wyatt, DC Montefiori, M Bilska, R Woodward, PD Markbam, JD Malley, TU Vogel, TM Allen, DI Watkins, N Miller, B Moss. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 2002 Mar 15;294(2):270-281. [ PubMed abs ]
RR Amara, JM Smith, SI Staprans, DC Montefiori, F Villinger, JD Altman, SP O'Neil, NL Kozyr, Y Xu, LS Wyatt, PL Earl, JG Herndon, JM McNicholl, HM McClure, B Moss, HL Robinson. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol. 2002 Jun;76(12):6138-6146. [ PubMed abs ]
RR Amara, F Villinger, SI Staprans, JD Ahman, DC Montefiori, NL Kozyr, Y Xu, LS Wyatt, PL Earl, JG Herndon, HM McClure, B Moss, HL Robinson. Different patterns of immune responses but similar control of simian human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol. 2002 Aug;76(15):7625-7631. [ PubMed abs ]
S Sadagopal, RR Amara, DC Montefiori, LS Wyatt, SI Staprans, NL Kozyr, HM McClure, B Moss, HL Robinson. Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breath and low-frequency T-cell response capable of coproducing gamma interferon and interleukin-2. J Virol. 2005 Mar;79(6):3243-3253. [ PubMed abs ]
Licensing Status: Available for licensing.
Portfolios: Devices/Instrumentation Devices/Instrumentation - Research Tools and Materials Infectious Diseases Infectious Diseases - Vaccines
For Additional Information Please Contact: Susan Ano Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: email@example.com Phone: 301-435-5515 Fax: 301-402-0220